Promising effect of Zolbetuximab and mFOLFOX6 Combination For Gastroesophageal Junction Adenocarcinoma
The SPOTLIGHT study, presented at ASCO GI, indicates promising effects of combining Zolbetuximab with mFOLFOX6 chemotherapy as first-line treatment for people with advanced gastroesophageal junction adenocarcinoma resistant to surgery. Kohei Shitara from the National Cancer Center Hospital East in Chiba, Japan, presents the results in this MEDtalk.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in